Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab, Lenvatinib, and GEMOX Neoadjuvant for Resectable ICC
NCT04669496Phase 3Active, not recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2021
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Zhongshan Hospital, Fudan University. Started Jan 2021; status: active, not recruiting.
02
Drugs
toripalimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04669496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04669496.